DES (Diethylstilbestrol) Info

DES (Diethylstilbestrol) Info We welcome everyone from the DES community -- Mothers, Daughters, Sons, 3rd Generation and all exposed! In some clinics, it was given to every pregnant patient.

DES Info Association:

The DES tragedy of in-utero exposure and its devastating effects on multiple generations must not be forgotten. The medical community need education about the sequela of DES Exposure. (1) know how to screen the DES exposed, (2) Know the continueing long term effects of DES exposure, and (3) Provide prompt care when DES Exposed patients develop complications.

** What is DES

(diethylstilbestrol)? **

DES (diethylstilbestrol), is a teratogenic and carcinogenic synthetic estrogen (Endocrine Disruptor) , is the world’s first major drug disaster. It was prescribed to millions of pregnant women for decades: from 1938 into the 1970s in the United States; and until the mid-1980s in parts of Latin America, Europe, Australia, and the Third World (Currently in Kenya). The currently proven effects of exposure include a rare vaginal cancer in DES Daughters; greater risk for breast cancer in DES Mothers; possible risk for testicular cancer in DES Sons, along with transgender and reproductive malformations; abnormal reproductive organs; infertility; high-risk pregnancies; Skeletal issues and an increased risk for breast cancer in DES Daughters. There are a number of other suspected effects, including auto-immune disorders, but many of these effects are still awaiting further research. For decades, Big Pharma claimed DES prevented miscarriages and problem pregnancies. It was sometimes given as an injection, but primarily it was prescribed in pill form. Never patented, DES was marketed under 200 different names, although the majority of the drug was actually produced by Eli Lilly. DES was sometimes even included in prescription prenatal vitamins. As early as 1938, studies showed that DES promoted cancer in lab animals. But at that time, people thought animal studies only provided a hint of what could happen in humans. Also, no one knew that drugs could cross the placenta and affect a baby in utero. (Note there was a 1941 mouse study that showed mice with absent or deformed fallopian tubes. The warning signs were there for humans.) In 1941, the original clinical uses for DES were to treat gonorrheal vaginitis, senile vaginitis, menopausal symptoms and to suppress lactation. Between 1941 and 1947, it was used for pregnancy without FDA approval. No controlled studies were ever conducted by the drug companies to determine the effectiveness or safety of DES for use during pregnancy, even after some scientists started questioning its efficacy in the 1950s. As early as 1953, research revealed that DES did not work (The Dieckmann Study) – that DES actually brought about higher rates of premature birth and infant mortality – yet DES continued to be prescribed to pregnant women for decades. This is because pharmaceutical companies continued to heavily promote DES use to doctors. The drug was a top moneymaker for Big Pharma. In the late 1960s, there was an unprecedented appearance of rare cancer in young women. Clear cell cancer (CCA) – a rare cancer of the vagina – was diagnosed in an age group never before found to develop it. (Normally elderly women developed CCA.) There were eight such cases at Massachusetts General Hospital in Boston alone. One of the mothers raised the question of whether her daughter's cancer might be connected to DES exposure in utero. Doctors discovered the DES link in 1971 and published their findings in the April 1971 issue of New England Journal of Medicine. News of the cancer cases made national headlines. However, the FDA did not act on this information until public pressure, including Congressional Hearings, forced the FDA to issue a warning about DES in November 1971. The drug was not banned for human use. DES was contraindicated for pregnancy by the FDA in 1972. It was not until September 2000 that the FDA finally withdrew its approval of DES for humans. Researchers are now investigating whether DES health issues are extending into the next generation, the so-called DES Grandchildren (Third Generation). As study results come in, there is growing evidence that this group has been adversely impacted by a drug prescribed to their grandmothers. To this day, not one drug company has ever apologized or accepted responsibility for the DES tragedy. Nevertheless, they have paid millions in out-of-court settlements and verdicts to DES Daughters and Sons who suffered injuries from their exposure. Please join us in our mission to continue to provide information to the DES exposed on DES information and other health related information along with pushing for more physician education to know how to care for the DES exposed. Also, we are continuing to push for more research! Our moto is "Knowledge is Power" DES Info Association is a free resource for Diethylstilbestrol Information and Research

“DISCLAIMER: THIS SITE DOES NOT PROVIDE MEDICAL ADVICE. The information on this site, including but not limited to text, graphics, images and other material, is for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. If you have any questions about how the information contained on this website may relate to you, you should seek the advice of a physician or other qualified health care professional.”

Thanks for being a top engager and making it on to my weekly engagement list! 🎉 Dianne Ackerman, Cynthia Irving, Jude De...
06/19/2026

Thanks for being a top engager and making it on to my weekly engagement list! 🎉 Dianne Ackerman, Cynthia Irving, Jude Denzer, David Barraza

DES Info: DES and pregnancy experienceHerbst AL, Hubby MM, Blough RR, Azizi F. “A comparison of pregnancy experience in ...
06/15/2026

DES Info: DES and pregnancy experience
Herbst AL, Hubby MM, Blough RR, Azizi F. “A comparison of pregnancy experience in DES-exposed and DES-unexposed daughters.” J Reprod Med. 1980 Feb;24(2):62-9. PMID: 7359503.
This article stated the following: “Comparison of evaluable first pregnancy outcome revealed full-term live birth to be more common among the unexposed (85%) than the exposed (47%). Premature live birth was experienced by 22% of the exposed but only 7% of the unexposed. Nonviable outcomes of stillbirth, neonatal death, miscarriage and ectopic pregnancy occurred in 31% of the exposed and 8% of the unexposed.” “Overall 82% of the exposed and 93% of the unexposed had at least one live offspring.”
https://journals.lww.com/obgynsurvey/citation/1980/07000/a_comparison_of_pregnancy_experience_in.23.aspx

For further information, please review the article online or contact DES Info Association at [email protected]. Please include the title of the article..



[email protected]

An abstract is unavailable. This article is available as a PDF only.

DES Info:  A  message from a DES Daughter who developed Clear Cell Adenocarcinoma of the Uterus.https://voices.uchicago....
06/06/2026

DES Info: A message from a DES Daughter who developed Clear Cell Adenocarcinoma of the Uterus.

https://voices.uchicago.edu/ccaregistry/contact/
I am a DES daughter who had a CCA of the uterus when I was 60. I am now 72.

I have just signed consent forms to participate in a research study with the University of Chicago and would like to encourage anyone in our DES community who has been diagnosed with any gynecological CCA to contact them and see if you are eligible to participate.

You do not have to live in the Chicago area. There are no financial costs to you.

I will be providing blood work and access to other related medical info. That is all. I have provided their contact info in a link.
University of Chicago is the only place I could find that is doing this kind of research.

Please join me and let's make something good happen from our exposure to DES and subsequent cancer.

Contact Contact Information Dezheng Huo, M.D., Ph.D., Principal Investigator Natalija Djordjevic, B.A., Research Coordinator Emails: [email protected] Phone: (773) 702-9607 Feel free to contact our office to register or for more information Related Sources of Information: National Cancer Ins...

Thanks for being a top engager and making it on to my weekly engagement list! 🎉 Mary Jane White, Jude Denzer, Lula Ather...
06/05/2026

Thanks for being a top engager and making it on to my weekly engagement list! 🎉 Mary Jane White, Jude Denzer, Lula Atherton, Dawn Gundlach, Charles Sultan

DES Info: Clear Cell Cervical Carcinoma to a Woman -  DES given as a Lactation SuppressionPalaiologos K, Theofrastou SS,...
06/04/2026

DES Info: Clear Cell Cervical Carcinoma to a Woman - DES given as a Lactation Suppression

Palaiologos K, Theofrastou SS, Gerovasileiou E, Flynn M. “A Rare Case of Clear Cell Cervical Carcinoma to a Woman, 50 Years After Diethylstilbestrol Exposure for Lactation Suppression.”
Cureus. 2021 Aug 26;13(8):e17468. doi: 10.7759/cureus.17468. PMID: 34589362; PMCID: PMC8464348.

This is an important finding to share. We have seen a lot of media coverage in Scotland where women given DES as lactation suppression have developed Cervical Carcinoma. Our physicians need to be aware of this and protocols updated to screen DES Exposed women.

The conclusion is so important: “We presented a case report of a woman who developed clear cell cervical carcinoma 50 years after ex-utero exposure to DES. Clear cell carcinoma of the ge***al tract should prompt the clinician to take a complete medical history, including DES exposure, to the patient.”

https://pubmed.ncbi.nlm.nih.gov/34589362/

DES Info: This case is an example of why DES Exposed women must have annual GYN Exams.

For further information, please review the article online or contact DES Info Association at [email protected]. Please include the title of the article.



[email protected]

Cureus 13(8): e17468.

A 73-year-old lady presented with post-menopausal bleeding and a suspicious-looking endocervical polyp. She had a loop biopsy of the cervix that showed clear cell cervical carcinoma, and she was referred to our Gynaecology oncology team for further management. Following imaging for staging and an MD...

DES Info: DES and ADHD Third GenerationKioumourtzoglou M, Coull BA, O’Reilly ÉJ, Ascherio A, Weisskopf MG. “Association ...
06/02/2026

DES Info: DES and ADHD Third Generation

Kioumourtzoglou M, Coull BA, O’Reilly ÉJ, Ascherio A, Weisskopf MG. “Association of Exposure to Diethylstilbestrol During Pregnancy With Multigenerational Neurodevelopmental Deficits.” JAMA Pediatr. 2018;172(7):670–677. doi:10.1001/jamapediatrics.2018.0727

https://pubmed.ncbi.nlm.nih.gov/29799929/

“Unfortunately, studies have shown a correlation between 3rd Generation DES Grandchildren and ADHD “A cohort study of 47 450 women in the Nurses’ Health Study II found significantly elevated odds for attention-deficit/hyperactivity disorder in the grandchildren (third generation) of users of diethylstilbestrol, a potent endocrine disruptor.”

For further information, please review the article online or contact DES Info Association at [email protected]. Please include the title of the article.



[email protected]

This study provides evidence that diethylstilbestrol exposure is associated with multigenerational neurodevelopmental deficits. The doses and potency level of environmental endocrine disruptors to which humans are exposed are lower than those of diethylstilbestrol, but the prevalence of such exposur...

DES Info: DES used in India - In animals!
05/30/2026

DES Info: DES used in India - In animals!

Qikhit Injection Use in Hindi || Diethylstibestrol Injection Uses in Veterinary || ...

DES Info: Just in - Breaking News!■ “Multigenerational Musculoskeletal Anomalies After In Utero Exposure to Synthetic Xe...
05/29/2026

DES Info: Just in - Breaking News!
■ “Multigenerational Musculoskeletal Anomalies After In Utero Exposure to Synthetic Xenohormones (Diethylstilbestrol, Ethinyl Estradiol and/or Progestins)” This is the first time that conge***al musculoskeletal malformations have been described in the grandchildren of women treated with xenohormones.

The epigenetic and hormonal mechanisms involved in the teratogenic effects of these endocrine disruptors are discussed. Conge***al musculoskeletal malformations (e.g., arm or hand hemimelia and agenesis cranium malformations were some of those noted. Moreover, the third generation is not spared.

Importantly, the third‐generation children often experienced the effects of a double exposure: i) the germ cells of the foetus who was exposed in utero, and ii) the hormonal treatment based on progestins taken by their mother (2nd generation) in case of fertility/pregnancy problems. This is extremely worrying because the descendants of women treated with DES represent more than 50 million people worldwide.

Therefore, the exposure to exogen s*x hormones and other widespread endocrine disruptor chemicals might negatively affect (and will affect) the life of hundreds of millions of people worldwide. (Authors : Marie‐Odile Soyer‐Gobillard, Laura Gaspari‐Sultan and Charles Sultan Posted Date: 25 May 2026 doi: 10.20944/preprints202605.1645.v1 https://www.preprints.org/frontend/manuscript/d86dee3d2999e98573358ff96d579622/download_pub)

DES Info: Increased breast cancer risk in DES DaughtersHilakivi-Clarke L. “Maternal exposure to diethylstilbestrol durin...
05/25/2026

DES Info: Increased breast cancer risk in DES Daughters

Hilakivi-Clarke L. “Maternal exposure to diethylstilbestrol during pregnancy and increased breast cancer risk in daughters.” Breast Cancer Res. 2014;16(2):208. doi: 10.1186/bcr3649. PMID: 25032259; PMCID: PMC4053091.
https://pubmed.ncbi.nlm.nih.gov/25032259/

This article states the following: “Explains why daughters of mothers who took synthetic estrogen diethylstilbestrol (DES) during pregnancy have two times higher breast cancer risk than women who were not exposed to it.”

“The mechanisms likely involve epigenetic alterations, such as increased DNA methylation and modifications in histones and microRNA expression. Further, these alterations may target genes that regulate stem cells and prevent differentiation of their daughter cells.”

“Recent findings in a preclinical model suggest that not only are women exposed to DES in utero at an increased risk of developing breast cancer, but this risk may extend to their daughters and granddaughters as well.”

For further information, please review the article online or contact DES Info Association at [email protected]. Please include the title of the article.



[email protected]

The idea that susceptibility to breast cancer is determined not only through inherited germline mutations but also by epigenetic changes induced by alterations in hormonal environment during fetal development is gaining increasing support. Using findings obtained in human and animal studies, this re...

DES Info: New England Journal of Medicine Article: DES link to Adenocarcinoma of the Va**na 1971Herbst AL, Ulfelder H, P...
05/23/2026

DES Info: New England Journal of Medicine Article: DES link to Adenocarcinoma of the Va**na 1971

Herbst AL, Ulfelder H, Poskanzer DC. “Adenocarcinoma of the va**na. Association of maternal stilbestrol therapy with tumor appearance in young women.” N Engl J Med. 1971 Apr 22;284(15):878-81. doi: 10.1056/NEJM197104222841604. PMID: 5549830.
https://pubmed.ncbi.nlm.nih.gov/5549830/

This is a very important article and the beginning of what we now call “The DES Tragedy”
“Between 1966 and 1969, however, seven girls 15 to 22 years of age with adenocarcinoma of the va**na (clear-cell or endometrial type) were seen at the Vincent Memorial Hospital.”

“There is a highly significant association between the treatment of the mothers with estrogen diethylstilbestrol during pregnancy and the subsequent development of adenocarcinoma of the va**na in their daughters (p less than 0.00001). “

All the mothers who took stilbestrol began therapy in the first trimester of pregnancy. They received either a constant dose administered throughout the pregnancy, or a continually increasing dose given almost to term.”

“The time of birth of these patients (1946 to 1951) coincides with the beginning of the widespread use of estrogens in support of high-risk pregnancy.”
For further information, please review the article online or contact DES Info Association at [email protected]. Please include the title of the article.

[email protected]

Adenocarcinoma of the va**na. Association of maternal stilbestrol therapy with tumor appearance in young women

Address

Dallas, TX

Alerts

Be the first to know and let us send you an email when DES (Diethylstilbestrol) Info posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to DES (Diethylstilbestrol) Info:

Share